Malaria vaccine rolled out in world’s worst-affected country
3 min read
Nigeria, which suffers the highest number of malaria-related deaths globally, has launched its first-ever malaria vaccine roll-out. The West African nation accounts for nearly one-third of all malaria deaths worldwide each year. The introduction of the R21/Matrix-M malaria vaccine marks a significant milestone in the country’s fight against the disease.
Malaria continues to be a major health crisis in Nigeria, with the World Health Organization (WHO) reporting that the country accounted for 27% of global malaria cases and 31% of malaria-related deaths in 2022. The vaccine, R21/Matrix-M, is the second malaria vaccine to receive WHO approval and is designed to help curb these alarming statistics. It is being administered to children aged 5 to 15 months, the group most vulnerable to the disease.
This vaccine, developed by the Jenner Institute at Oxford University, has shown to be 75% effective in preventing malaria, making it one of the most promising tools in the fight against the disease. However, health experts emphasize that it should be used in conjunction with other malaria prevention measures, such as mosquito nets and insecticides, to achieve the best results in reducing the malaria burden.
The initial roll-out of the vaccine began in two of Nigeria’s most affected states: Bayelsa and Kebbi. Plans are in place to extend the vaccination program across the country by the end of next year. The vaccine’s distribution marks a crucial step toward addressing one of the world’s most severe public health challenges.
The first child to receive the vaccine was 11-month-old Happiness Idia-Wilson’s son, who was vaccinated in a ceremony in Bayelsa. She expressed her support for the vaccine, saying she was doing it “for the safety of the child, for him to be protected.” Idia-Wilson added that she would encourage other mothers to get their children vaccinated as well, emphasizing the importance of the vaccine for their health.
To ensure widespread acceptance and understanding, local health officials in Bayelsa are conducting health campaigns in all local languages to promote the vaccine’s use. Bayelsa’s Commissioner for Health, Prof Seiyefa Brisibe, stressed the importance of these efforts to educate the population about the vaccine and the critical role it plays in combating malaria.
The fight against malaria is particularly urgent in sub-Saharan Africa, where the disease remains one of the leading causes of death. In 2022, the WHO reported that the region accounted for 95% of global malaria deaths, with young children and pregnant women being the most at risk. Nigeria’s high malaria-related death toll, combined with the substantial economic losses caused by the disease, highlights the importance of the new vaccine. The Nigerian government estimates that malaria costs the country $1.1 billion annually in lost productivity and healthcare expenses.
Despite the vaccine’s approval and the positive impact it may have, Nigeria was not included in the initial WHO roll-out of the R21/Matrix-M vaccine to 12 other African countries. This delay in Nigeria’s inclusion has led to a sense of urgency within the country’s healthcare community, as it grapples with the overwhelming malaria burden. However, WHO representatives in Nigeria are optimistic about the vaccine’s potential to reduce malaria-related deaths in the country. Dr. Walter Mulombo, WHO’s representative in Nigeria, expressed confidence that the R21/Matrix-M vaccine, when used alongside other preventive measures, will substantially decrease the malaria burden in the country and bring Africa closer to achieving the goal of a malaria-free continent.
The introduction of the R21/Matrix-M vaccine is also significant beyond Nigeria’s borders. Earlier this year, other African nations such as Ivory Coast and the Democratic Republic of Congo began using the vaccine as part of their malaria control efforts. This regional adoption of the vaccine reflects a growing commitment to addressing malaria at the continental level, with the aim of reducing the disease’s devastating toll on African populations.
Overall, the roll-out of the R21/Matrix-M vaccine in Nigeria represents a hopeful step in the battle against malaria, a disease that has caused untold suffering for millions of families across the country. While it is still early in the vaccine’s distribution, the potential to save lives and reduce the economic burden of malaria in Nigeria is immense. As the vaccine reaches more children and is combined with other preventive tools, there is hope that it will play a pivotal role in the fight against malaria, both in Nigeria and throughout Africa.
About The Author
